[Tree] US lawmakers seek FBI briefing on GenScript Biotech's links to China amid concerns over Chinese influence, US lawmakers express concerns over FDA's drug inspection program in India and China, U.S. FDA inspection of Divi's Labs facility in Visakhapatnam, Gland Pharma's Hyderabad facility and US FDA observations, Cipla's plans to supply the US market from its China facility
Version 0.55 (2024-07-28 07:59:43.714000)
updates: Inclusion of Cipla's plans to supply the US market from its China facility
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.54 (2024-07-25 10:14:31.694000)
updates: Gland Pharma's Hyderabad facility receives two US FDA observations
- ➔
- ➔
- ➔
- ➔
Version 0.53 (2024-07-19 14:09:42.663000)
updates: US lawmakers express concerns over FDA's drug inspection program in India and China, FDA inspects Divi's Labs facility in Visakhapatnam
- ➔
- ➔
- ➔
Version 0.52 (2024-06-25 02:55:17.368000)
updates: US lawmakers express concerns over FDA's drug inspection program in India and China
- ➔
- ➔
Version 0.51 (2024-05-31 19:57:45.225000)
updates: US lawmakers request FBI briefing on GenScript Biotech
- ➔
Version 0.5 (2024-05-31 15:53:00.349000)
updates: Includes concerns about filling the void left by Chinese biotech firms
- ➔
- ➔
Version 0.49 (2024-05-17 12:53:23.675000)
updates: The US House Committee on Oversight and Accountability has approved the bill
- ➔
Version 0.48 (2024-05-15 21:53:25.175000)
updates: Legislation on biotechnology data security, taxpayer-funded projects, and federal grants
- ➔
Version 0.47 (2024-05-15 19:55:56.994000)
updates: Legislation approved to restrict business with BGI and WuXi AppTec
- ➔
Version 0.46 (2024-05-15 16:58:23.488000)
updates: US House committee supports bill to restrict BGI and WuXi AppTec
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.45 (2024-05-12 05:48:01.902000)
updates: Lab-leak theory gains support from key figures
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.44 (2024-05-08 03:15:51.722000)
updates: Classified documents suggest COVID-19 originated from Wuhan lab leak
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.43 (2024-05-02 22:03:24.589000)
updates: New documents reveal heavy redactions in US documents related to research conducted at the Wuhan lab before the pandemic; Emails allegedly show Facebook censoring claims about the lab leak theory [cae5f3a9]
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.42 (2024-04-30 16:23:21.002000)
updates: Inclusion of information about Chinese scientist Zhang Yongzhen being locked out of his lab and staging a protest [8a513497]
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.41 (2024-04-30 16:10:32.392000)
updates: The scientist who developed China's first COVID-19 vaccine has been expelled from parliament and is facing disciplinary charges.
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.4 (2024-04-29 04:50:24.093000)
updates: Information about China's vaccine developers and mRNA technology
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.39 (2024-03-14 03:08:42.322000)
updates: BIO to sever ties with WuXi AppTec
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.38 (2024-03-07 20:27:29.963000)
updates: Stock prices of Chinese biotech firms drop after US panel advances ban bill
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.37 (2024-03-07 02:21:56.714000)
updates: US Senate Committee passes bill restricting Chinese biotech companies, Wuxi AppTec stock drops
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.36 (2024-02-24 16:24:42.737000)
updates: US legislation aims to regulate Chinese biotech companies' access to American genetic information
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.35 (2024-02-24 16:22:58.089000)
updates: US lawmakers are increasingly concerned about America's failure to compete with China in the field of biotechnology and are taking action to address the issue. Bills have been introduced in both the House and Senate to prevent 'foreign adversary biotech companies of concern' from conducting business with federally funded medical providers. The legislation specifically targets four Chinese-owned companies, including BGI and WuXi AppTec, citing their ties to the Chinese military and concerns about data sharing with the Chinese government. Critics argue that restrictions on Chinese companies could hinder advancements in biotech that could bring greater benefits. However, supporters of the legislation argue that it is crucial to protecting US interests, as advancements in biotechnology can have both economic benefits and rapid changes in military capabilities and tactics. The Biden administration has also emphasized the importance of advancing biotechnology and biomanufacturing, while the Chinese government has plans to develop a 'national strategic technology force' in biotech. The debate over biotechnology is taking place against the backdrop of strained US-China relations, which are already fraught with issues such as trade disputes, the COVID-19 pandemic, cybersecurity concerns, and militarization in the South China Sea.
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.34 (2024-02-20 08:19:07.443000)
updates: US lawmakers introduce bills to restrict Chinese biotech companies and address broader concerns about China
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.33 (2024-02-20 04:16:39.887000)
updates: US lawmakers introduce bills to address China's biotech threat
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.32 (2024-02-20 01:17:06.620000)
updates: US lawmakers are taking action to address the threat posed by China's biotech industry. They are introducing legislation to restrict Chinese biotech companies from doing business with federally funded medical providers, mandating investment disclosures, requiring public companies to disclose their reliance on China in their supply chains, and changing how Wall Street invests in Chinese companies. These actions are driven by concerns about national security, data privacy, and unfair competition.
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.31 (2024-02-20 00:17:27.732000)
updates: US lawmakers are introducing legislation to address the threat posed by China's biotech industry. The bills target Chinese-owned companies and aim to protect US interests and national security. The Biden administration supports biotechnology advancements, while the Chinese government sees biotech as important for investment and technological independence. There are concerns that restrictions on Chinese companies could impede biotech advances, but supporters argue that the legislation is necessary to safeguard federal data and discourage unfair competition. US lawmakers are also taking other actions to address the broader threat posed by China, including raising alarms about China's military maneuvers and filing bills to ban Chinese biotech companies from federal contracts. Efforts are also underway to mandate investment disclosures and change how Wall Street invests in Chinese companies. Additionally, a bill has been introduced to ease reporting requirements for small businesses and close loopholes for Chinese shell companies operating in the United States. Some experts caution that shutting out Chinese companies could hinder efforts to cure diseases and feed the world's population, while others raise concerns about Beijing's lack of transparency and unfair market practices. A recent congressional investigation has found that American venture capital firms have invested over $1 billion in China's semiconductor industry, and another report accuses venture capital firms of channelling over $3 billion into Chinese technology companies allegedly supporting Beijing's military activities and human rights violations. A bipartisan group of US lawmakers has called for sanctions on Chinese biotech firm WuXi AppTec and its affiliate WuXi Biologics, citing their links to China's Communist Party and military. Overall, US lawmakers are taking a comprehensive approach to address the threat posed by China's biotech industry, driven by concerns about national security, data privacy, and unfair competition.
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.3 (2024-02-19 23:16:32.610000)
updates: New information about bipartisan efforts to address the threat posed by China's biotech industry
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.29 (2024-02-19 18:16:39.729000)
updates: US lawmakers introduce bills to restrict Chinese biotech companies
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.28 (2024-02-19 14:19:09.400000)
updates: US lawmakers introduce bills to restrict Chinese biotech companies
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.27 (2024-02-19 08:18:17.745000)
updates: US lawmakers introduce bills to restrict Chinese biotech companies
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.26 (2024-02-19 07:17:29.403000)
updates: US lawmakers introduce legislation to restrict Chinese biotech companies and address investment concerns
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.25 (2024-02-19 05:16:30.804000)
updates: US lawmakers introduce bills to address China's biotech threat
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.24 (2024-02-15 18:17:27.918000)
updates: US lawmakers visit Massachusetts to raise alarms about China's threat to US biotech. Bill filed to ban Chinese biotech giant Beijing Genomics Institute from federal contracts. Concerns raised about Chinese biotech firms accessing personal medical data of Americans. Biotech companies shortening supply chains and producing drugs domestically. Bipartisan bill introduced to mandate private funds to disclose investments in China. Legislation proposed to require public companies to disclose reliance on China in supply chains. Efforts to change how Wall Street invests in Chinese companies. Opposition to pension investments in China. Congressional investigation finds American venture capital firms invested in China's semiconductor industry. Report accuses venture capital firms of channelling funds into Chinese technology companies supporting Beijing's military activities and human rights violations. Bipartisan group of lawmakers calls for sanctions on WuXi AppTec and WuXi Biologics
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.23 (2024-02-14 05:54:18.992000)
updates: Shares of WuXi AppTec and WuXi Biologics slump in Hong Kong as US lawmakers call for a formal probe
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.22 (2024-02-12 20:27:29.232000)
updates: US lawmakers call for sanctions on Chinese biotech firm WuXi AppTec
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.21 (2024-02-10 09:14:15.225000)
updates: US lawmakers accuse VC firms of funding Chinese military firms
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.2 (2024-02-09 14:16:56.715000)
updates: Congressional investigation reveals US venture-capital firms funded Chinese companies linked to human rights abuses and Chinese military
- ➔
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.19 (2024-02-08 15:14:30.157000)
updates: Inclusion of recent congressional investigation on American firms' investments in Chinese chips
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.18 (2024-01-18 19:44:03.285000)
updates: Inclusion of a new bill targeting Chinese shell companies
- ➔
- ➔
- ➔
- ➔
Version 0.17 (2023-11-30 03:43:49.802000)
updates: Inclusion of opposition to pension investments in China
- ➔
- ➔
- ➔
Version 0.16 (2023-11-16 09:50:47.236000)
updates: Republican Congressman Mike Gallagher's efforts to change how Wall Street invests in Chinese companies
- ➔
- ➔
- ➔
Version 0.15 (2023-11-14 17:14:08.404000)
updates: Add information about Representative Brad Sherman's draft legislation on risk reporting and crypto tax reforms
- ➔
- ➔
Version 0.14 (2023-11-13 23:04:57.944000)
updates: Restructured and clarified information, added details
- ➔
Version 0.12 (2023-11-03 04:47:33.658000)
updates: The story now includes information about China's Ministry of Commerce hoping for the US to not decouple from China and cancel investment restrictions, concerns expressed by US banks and manufacturers, the impact of decoupling on global economy and trade order, the European Union's move to review wind power products from Chinese companies, and the Ministry of Commerce's focus on foreign capital market access.
Version 0.11 (2023-11-01 01:21:25.835000)
updates: Restructured and streamlined information to provide a comprehensive narrative
Version 0.1 (2023-11-01 00:23:01.883000)
updates: The original story was about US lawmakers urging Yellen to speed up China outbound investment rules. The new narrative includes additional information about US investment groups calling for changes to China investment rules.
- ➔
Version 0.09 (2023-10-31 13:33:24.824000)
updates: The title has been modified to include both investment groups and lawmakers, and the story has been restructured and expanded to include additional details from the source article.
Version 0.08 (2023-10-31 12:22:01.368000)
updates: Restructured and streamlined information to provide a comprehensive narrative
Version 0.07 (2023-10-31 11:23:41.072000)
updates: Restructured and streamlined information, eliminated repetitive points, maintained clear and objective perspective, logical flow for enhanced reading and comprehension
Version 0.06 (2023-10-31 10:20:21.830000)
updates: Combining information from investment groups and lawmakers
- ➔
- ➔
Version 0.05 (2023-10-20 04:35:13.592000)
updates: The article provides more details on the concerns of US investment groups and their push for changes to the proposed limits on investment in China.
- ➔
Version 0.04 (2023-10-19 14:26:34.804000)
updates: The new narrative includes information about the roaring US economy and the trend of home bias in investing.
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.03 (2023-10-18 09:35:13.679000)
updates: The new narrative includes information about the US economy outperforming China, the trend of 'home bias' in investing, and the impact of international politics on the attractiveness of US assets.
- ➔
- ➔
- ➔
- ➔
- ➔
Version 0.02 (2023-10-18 08:35:10.787000)
updates: Added information about investors flocking to the US economy amid global uncertainty
- ➔
- ➔
- ➔
- ➔
Version 0.01 (2023-10-17 10:08:03.934000)
updates: The article supports the view of billionaire American investors
- ➔
- ➔
- ➔